ARDELYX, INC. (ARDX) earnings date
Feb 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 8 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | after close | 34 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | after close | 30 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | after close | 50 | 8-K |
| Q3 FY2025 | Thu, Oct 30, 2025 | after close | 30 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | after close | 35 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | after close | 31 | 8-K |
| Q4 FY2024 | Thu, Feb 20, 2025 | before open | 51 | 8-K |
What they guided beta
| Q3 FY2026 | "Revenue for XPHOZAH ® (tenapanor) during the third quarter of 2026 was $29.2 million, reflecting year-over-year growth of 7%. 2026 Full-Year Guidance and Outlook" exhibit |
| Q3 FY2026 | "Full-year 2026 revenue guidance for IBSRELA reiterated to be between $350 and $370 million." exhibit |
| Q3 FY2026 | "Full-year 2026 revenue guidance for XPHOZAH reiterated to be between $110 and $120 million." exhibit |
| Q3 FY2026 | "Full-year 2026 operating expense guidance reiterated to be below $500 million." exhibit |
| Q3 FY2026 | "The Company is on track to announce topline data in the second half of 2027." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents and investments as of June 30, 2026 Revising FY 2026 and long-term guidance Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., August 6, 2026 – Ardelyx Inc. (Nasdaq: ARDX), (“Ardely" exhibit |
| Q2 FY2026 | "Full-year 2026 revenue guidance for IBSRELA revised to be between $350 and $370 million." exhibit |
| Q2 FY2026 | "Full-year 2026 revenue guidance for XPHOZAH reiterated to be between $110 and $120 million." exhibit |
| Q2 FY2026 | "The Company is on track to complete enrollment by the end of 2026 and to announce top-line data in the second half of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ARDX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ARDX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ARDX/"><img src="https://veritasdata.dev/embed/ARDX.svg" alt="ARDX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ARDX/)
Script
<script async src="https://veritasdata.dev/embed/ARDX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ARDX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.